After the clinical implementation of amyloid-β-targeting therapies for people with cognitive impairment due to Alzheimer’s disease (AD), there is an urgent need to efficiently identify this patient ...
Alzheimer's disease (AD) has a long preclinical phase in which multiple pathophysiological changes are observable before the onset of overt cognitive impairment 1,2,3. However, it has been widely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results